MAJOR COMPARISON
I need to ALERT you all to the fact that Retrophin announced their Proeinuria results for a very smilar phase II trial for Kidney Disease using a diffent combination of 2 receptor blockers. Basically they achieved a 44% mean reduction and the share priced rocketed from $16 to $21 and they put on a approx US$100m in value. See the chart
If Dimerix interim results for DMX200 shows a reduction in preinuria as per the animal model of 50% or more using the angiotensin Il Type 1 (AT1R) and the chemokine 2 receptors (CCR2) then its market cap will soar from $20 million and in line with its US peers just on the potential alone and its competitive advantage in this space. That’s why I place a value closer to $100m market cap on positive results.
The rat model data was very impressive. See link.
http://dimerix.com/wp-content/uploads/15.05.13.Sun-Biomedical-to-Acquire-Dimerix-Bioscience1.pdf
GET SET
Dimerix vs Retrophin
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.010(2.44%) |
Mkt cap ! $220.2M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 42.0¢ | 39.5¢ | $839.4K | 2.070M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35000 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 83901 | 4 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| DXB (ASX) Chart |